Skip to Content
Merck
All Photos(1)

Documents

SML1260

Sigma-Aldrich

HLM006474

≥98% (HPLC)

Synonym(s):

7-[(4-Ethoxy-3-methylphenyl)(2-pyridinylamino)methyl]-2-methyl-8-quinolinol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C25H25N3O2
CAS Number:
353519-63-8
Molecular Weight:
399.48
MDL number:
MFCD02168344
UNSPSC Code:
12352200
PubChem Substance ID:
329825752
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

storage temp.

2-8°C

SMILES string

CC1=CC(C(NC2=NC=CC=C2)C3=C(O)C(N=C(C)C=C4)=C4C=C3)=CC=C1OCC

InChI

1S/C25H25N3O2/c1-4-30-21-13-11-19(15-16(21)2)23(28-22-7-5-6-14-26-22)20-12-10-18-9-8-17(3)27-24(18)25(20)29/h5-15,23,29H,4H2,1-3H3,(H,26,28)

InChI key

CYNZBLNMIJNBSF-UHFFFAOYSA-N

Application

HLM006474 has been used as an E2 factor (E2F) inhibitor in human nasopharyngeal carcinoma hone-1 cells and T. annulata-infected TBL20 cells.

Biochem/physiol Actions

HLM006474 activates p53 and induces DNA damage and apoptosis in mouse tumor models.
HLM006474 is a pan-E2F transcription factor inhibitor. E2F s part of the CDK/Rb/E2F pathway. When phosphorylated by CDKs, the tumor suppressor retinoblastoma protein (Rb) is inactivated, releasing E2Fs and allowing cell cycle progression. HLM006474 inhibited DNA-binding of all E2F complexes and down-regulated expression of E2F4 protein. HLM006474 induced apoptosis of A375 melanoma cells and synergized with paclitaxel in lung cancer cell lines.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Florian Rouaud et al.
Cell death & disease, 9(5), 527-527 (2018-05-11)
Melanoma is one of the most lethal cancers when it reaches a metastatic stage. Despite advancements in targeted therapies (BRAF inhibitors) or immunotherapies (anti-CTLA-4 or anti-PD1), most patients with melanoma will need additional treatment. Thus, there is an urgent need

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service